KMPH - KemPharm Non-GAAP EPS of -$0.19 misses by $0.05 revenue of $1.3M misses by $0.45M
- KemPharm press release ( NASDAQ: KMPH ): Q2 Non-GAAP EPS of -$0.19 misses by $0.05 .
- Revenue of $1.3M (-89.2% Y/Y) misses by $0.45M .
- As of June 30, 2022, total cash, cash equivalents and investments were $114.5 million, which was a decrease of $4.6 million compared to $119.1 million as of March 31, 2022, driven in part by increased spending on third-party research and development costs related to the KP1077 clinical trial program, and other expenses related to the arimoclomol asset acquisition.
- Based on the Company’s current operating forecast, existing cash, cash equivalents and investments are expected to be sufficient to continue operations beyond 2025.
- Shares -2.91% .
For further details see:
KemPharm Non-GAAP EPS of -$0.19 misses by $0.05, revenue of $1.3M misses by $0.45M